Regenxbio (RGNX) announced the completion of enrollment in the Atmosphere and Ascent pivotal studies evaluating surabgene lomparvovec in wet age-related macular degeneration using subretinal delivery. Topline data is expected in the fourth quarter of 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
- Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
- Regenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trial
- Regenxbio FDA delay ‘not a needle mover,’ says Leerink
- Strategic Developments and Partnerships Bolster RegenXBio’s Buy Rating Amid Regulatory Delay